This medication is not approved for use in children, and has not been adequately studied in this age group. In animal studies, the drug caused bone and teeth problems when given to young mice and dogs. However, it is unknown whether it would have the same effects in children. Talk to your child's healthcare provider about the risks and benefits of using axitinib in children.
Is It Safe for Older Adults?
Axitinib can be used in older adults. Approximately 34 percent of people in axitinib clinical trials were 65 years of age or older. In these studies, older adults responded to the medicine no differently than younger adults. However, some older adults may be more sensitive to the effects of this medicine, and may have an increased risk for axitinib side effects.
Are There Off-Label Axitinib Uses?
On occasion, healthcare providers may recommend axitinib for something other than the approved uses. This is called an "off-label" use. At this time, there are no well-accepted off-label uses for axitinib.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Inlyta [package insert]. New York, NY: Pfizer, Inc.;2012 January.
Pfizer Press release. U.S. Food and Drug Administration Approves Pfizer's Inlyta (axitinib) for Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC). January 27, 2012. Available at: http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp#guid=20120127005774en&source=RSS_2011&page=1. Accessed February 3, 2012.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click